Omega Therapeutics Kicks Start Trading On NASDAQ
On the heels of a $126 million crossover round in March, Flagship Pioneering-backed Omega Therapeutics Inc (NASDAQ:OMGA) has priced a $125.8…
London-Listed MaxCyte Makes NASDAQ Debut Today
MaxCyte Inc (NASDAQ:MXCT) is already trading on London’s AIM, but now, it debuted on NASDAQ after pricing a $176 million…
Elon Musk’s Neuralink Raises $205M In Series C Funding
Tesla Inc (NASDAQ: TSLA) CEO Elon Musk-led brain-machine interface startup said on Thursday it has secured $205 million in fresh funding — its largest so far.
Icosavax Kicks Off NASDAQ Debut; Trading Almost 150% Higher On IPO Price Of $15
Icosavax Inc (NASDAQ:ICVX) priced an upsized $182 million IPO, which had initially penciled in a $100 million raise. The new…
Tesla Co-Founder’s Battery Recycling Business Raises $700M In Series C Funding
Redwood Materials, founded by Tesla Inc (NASDAQ: TSLA) co-founder JB Straubel, has raised another $700 million for its electric vehicle battery recycling push.
Super Micro Computer Filing Shows Co. Entered Credit Deal With CTBC Bank For ~$40.7M
Super Micro Computer Inc., Taiwan (the “Subsidiary”), a Taiwan corporation and wholly-owned subsidiary of Super Micro Computer, Inc. (the “Company) was party to (i) that certain credit agreement, dated
British American Tobacco’s Btomorrow Ventures Leads $25.4M Series A For Cannabinoid Biotech Co. Trait Bio
Trait Biosciences, a leading cannabinoid biotechnology research organization, announced that it has completed a C$31 million ($25.46 million) Series A financing round led by the corporate venturing unit of British American Tobacco (NYSE: BTI), Btomorrow Ventures, and backed by Gotham Green Partners.
Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding
Intersect ENT Inc (NASDAQ:XENT) expects Q2 sales of approximately $27.3 million, slightly below the consensus estimate of $28.02 million. Record…
Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet
In December 2019, Kodiak Sciences Inc (NASDAQ:KOD) entered into a funding agreement with Baker Bros Advisors LP, wherein Baker Bros agreed…
Kodiak Sciences Reported in 8-K Filing that Baker Bros Acknowledged in a Letter that Second Funding Amount Would Not Paid; Royalty Amount on Sales of KSI-301 Would be Reduced from $1.025B to $450M
In December 2019, Kodiak Sciences Inc. together with its subsidiary Kodiak Sciences GmbH (collectively, "Kodiak") entered into a fundinga greement (the "Funding Agreement") with certain assignees of Baker Bros.